Qulipta (Atogepant) Patent Expiration, LOE Window & CMS Spending

Qulipta (Atogepant) by AbbVie: FDA Orange Book core substance LOE 2035-09-28 (last listed 2043-02-27), 0 AB generics, $427.4M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAbbVie
FDA Application & PathwayN215206 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2035-09-28
Last Listed Patent or Exclusivity Date2043-02-27
Orange Book Patents (*PED Extensions)9 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$427.4M
2024 Medicare Part D Spend$260.3M
2024 Medicaid Spend$167.1M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.